investigational device exemptions 21 cfr part 812 l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Investigational Device Exemptions 21 CFR Part 812 PowerPoint Presentation
Download Presentation
Investigational Device Exemptions 21 CFR Part 812

Loading in 2 Seconds...

play fullscreen
1 / 30

Investigational Device Exemptions 21 CFR Part 812 - PowerPoint PPT Presentation


  • 210 Views
  • Uploaded on

A Review for OCRA US RAC Study Group September 2005 Ginger Clasby, MS Promedica International gclasby@promedica-intl.com 714-799-1617 x 25. Investigational Device Exemptions 21 CFR Part 812. IDE About the Regulation.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Investigational Device Exemptions 21 CFR Part 812' - maddock


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
investigational device exemptions 21 cfr part 812

A Review for OCRA US RAC Study Group

September 2005

Ginger Clasby, MS

Promedica International

gclasby@promedica-intl.com

714-799-1617 x 25

Investigational Device Exemptions21 CFR Part 812
ide about the regulation
IDEAbout the Regulation
  • Provides procedures for conduct of clinical studies for unapproved devices
  • Exempts products from 510(k) or PMA approval requirements:
    • Registration, listing, interstate distribution
    • Labeling
    • GMPs
  • Applies to most studies to determine device safety & effectiveness
when ide application not required clinical study situations
When IDE Application Not RequiredClinical Study Situations
  • Device legally marketed for indicated use
    • Marketing preference studies
    • Market seeding studies
  • Device is substantially equivalent to pre 1976 commercially distributed device
  • Device is non-significant risk & IRB has approved study
  • Many diagnostic devices
  • Veterinary devices
  • Custom device
defining device types significant or non significant risk
Defining Device TypesSignificant or Non-Significant Risk?
  • Significant Risk: device has potential for serious risk to patient health, safety or welfare
    • Implants
    • Products supporting/sustaining life
    • Products with substantial role in diagnosing, curing mitigating or treating disease (or preventing impairment of human health)
  • Non-Significant Risk: all other devices
defining device types significant or non significant risk5
Defining Device TypesSignificant or Non-significant Risk?

How to decide?

Sponsor makes initial determination; IRB makes final call

regulatory differences significant vs non significant risk
Regulatory DifferencesSignificant vs. Non-significant Risk
  • Significant Risk Devices require FDA (IDE) & IRB approval prior to clinical study initiation
  • Non-Significant Risk Devices require only IRB approval prior to clinical study initiation
    • IDE presumed, unless FDA notified Sponsor that application is required
ide application contents administrative details
IDE Application ContentsAdministrative Details
  • Sponsor responsibility
  • 3 copies of submission required
  • All correspondence related to IDE sent by registered mail or by hand
  • IDE approval required prior to study initiation
ide application contents an overview
IDE Application ContentsAn Overview
  • Sponsor name & address
  • Report of prior investigations & investigational plan
  • Description of methods, facilities, controls used for device manufacture, processing, packaging, storage & use
  • Names of proposed investigators & example of proposed investigator agreements
  • Certification that all investigators will sign agreement prior to study participation
ide application contents an overview9
IDE Application ContentsAn Overview
  • List of name, address & chairperson of each IRB reviewing study
  • If device will be “sold”, amount to be charged and rationale for why sale does not constitute commercialization
  • Environmental exemption/assessment
  • Proposed device labeling
    • “Caution – Investigational Device Limited by Federal (or US) Law to Investigational Use”
  • Copies of all informed consent documents
ide contents report of prior investigations
IDE ContentsReport of Prior Investigations
  • Reports of all prior clinical, animal & lab testing of device – should be adequate to justify proposed study
  • Bibliography of related publications
  • Summary of unpublished info
  • Non-clinical lab studies (in compliance with GLP)
ide contents investigational plan
IDE ContentsInvestigational Plan
  • Study purpose
  • Proposed protocol
  • Risk analysis
  • Device description
  • Monitoring procedures
  • Labeling
  • Consent materials
ide contents investigational plan12
IDE ContentsInvestigational Plan
  • IRB info
  • Info on core labs, reading centers, etc.
  • Add’l records & reports
ide review approval fda s considerations
IDE Review/ApprovalFDA’s Considerations
  • Approval/disapproval decision
  • Rendered in writing
  • Rendered  30 days of FDA receipt
  • Approval may be denied/rescinded if:
    • Sponsor fails to comply with applicable regulations
    • Sponsor is non-responsive to requests for add’l info
    • Subject risks outweigh benefits
    • Unreasonable to proceed due to inadequacy of investigational plan, manufacturing or monitoring
prohibited practices under ide sponsors investigators
Prohibited Practices Under IDESponsors & Investigators
  • Promotion of investigational product
  • Representing device as safe or effective for use in the study
  • Commercializing device by charging more than cost-recovery
  • Unduly prolonging study
    • Enrolling more subjects than necessary
ide supplements necessary when
IDE SupplementsNecessary When:
  • Changes made to investigational plan that may affect:
    • Scientific soundness of study
    • Rights, safety or welfare of study subjects
  • Changes in device design
  • Changes in device manufacturing
  • Addition of study investigators
treatment ide appropriate when
“Treatment” IDEAppropriate When:
  • Device intended to treat or diagnose serious or life-threatening condition
  • No satisfactory alternative available
  • Controlled clinical trials in progress under IDE
    • Or when trials completed & FDA review of request to market is pending
  • Sponsor actively pursuing device marketing approval with FDA
sponsor responsibilities subpart c
Sponsor ResponsibilitiesSubpart C
  • Selection of qualified investigators & maintenance of ongoing communications
  • Appropriate monitoring of study
    • Special emphasis on device-related adverse events
  • Confirmation of IRB review/approval
  • Submission of IDE application to FDA
  • Prompt notification of significant new information to FDA, IRB
sponsor responsibilities subpart g records
Sponsor ResponsibilitiesSubpart G – Records
  • Maintenance of records:
    • Study-related correspondence
    • Device shipment/disposition
    • Signed investigator agreements & financial disclosure info
    • Non-significant risk justification (if applicable)
    • Adverse device effects & complaints
  • Record retention ≥ 2 yr after study completion or date no longer required for PMA application
  • Record custody transferable with notice to FDA
sponsor responsibilities subpart g inspections
Sponsor ResponsibilitiesSubpart G – Inspections
  • Must permit access by FDA employees to inspect facility where devices are held
  • Must permit access by FDA employees to inspect & copy study-related records
sponsor responsibilities subpart g reports
Sponsor ResponsibilitiesSubpart G – Reports
  • Unanticipated adverse device effects – 10 working days
  • Withdrawal of IRB approval – 5 working days
  • Withdrawal of FDA approval – 5 working days
  • Current investigator list – every 6 months
  • Progress reports – at least yearly
  • Device recalls & disposition – 30 working days
sponsor responsibilities subpart g reports21
Sponsor ResponsibilitiesSubpart G – Reports
  • Study completion (significant risk) - 30 working days
  • Final report - 6 months
  • Use of device without written consent – 5 working days
  • Significant risk determination – 5 working days
irb responsibilities subpart d
IRB ResponsibilitiesSubpart D
  • Membership, duties & functions in accordance with 21 CFR 56
  • Review of research
    • Initial review prior to study initiation
    • Significant risk determination, if necessary
    • Continuing review throughout study
irb responsibilities subpart g records reports
IRB ResponsibilitiesSubpart G – Records & Reports
  • Records maintained in accordance with 21 CFR 56
irb responsibilities subpart g inspections
IRB ResponsibilitiesSubpart G – Inspections
  • Must permit access by FDA employees to inspect & copy study-related records
investigator responsibilities subpart e
Investigator ResponsibilitiesSubpart E
  • Compliance with:
    • Investigational plan
    • Investigator agreement(s)
    • Applicable FDA regulations
  • Protection of subject rights & welfare
  • Control of investigational devices
  • Obtaining consent in accordance with 21 CFR part 50

Repeated noncompliance with assigned responsibilities may result in investigator disqualification by FDA

investigator responsibilities subpart g records
Investigator ResponsibilitiesSubpart G – Records
  • Maintenance of records:
    • Study-related correspondence
    • Product receipt, use, or disposition
    • Subject case records
    • Protocol & amendments
  • Record retention ≥ 2 yr after study completion or date no longer required for PMA application
  • Record custody transferable with notice to Sponsor, FDA
investigator responsibilities subpart g inspections
Investigator ResponsibilitiesSubpart G – Inspections
  • Must permit access by FDA employees to inspect facility where devices are held
  • Must permit access by FDA employees to inspect & copy study-related records
  • Must permit access by FDA employees to inspect & copy records identifying subjects, if:
    • Suspicion that adequate consent was not obtained
    • Required investigator reports incomplete, inadequate, false
investigator responsibilities subpart g reports
Investigator ResponsibilitiesSubpart G - Reports
  • Unanticipated adverse device effects – 10 working days
  • Withdrawal of IRB approval – 5 working days
  • Progress reports – at least yearly
  • Deviations from investigational plan – 5 working days
  • Device use without documentation of consent – 5 working days
  • Final report - 3 months
ide regulation reference documents links www fda gov cdrh
IDE RegulationReference Documents & Links (www.fda.gov/cdrh)
  • Guidance on IDE Policies & Procedures (1/1998)
  • Early Collaboration Meetings Under FDA Modernization Act (FDAMA), Final Guidance for Industry & CDRH Staff (2/2001)
  • Guidance on Significant & Non-Significant Risk Device Studies 7/25/86 (D86-1)
  • The Least Burdensome Provisions of FDA Modernization Act of 1997: Concept & Principles; Draft Guidance for FDA & Industry (5/3/2001)
ide regulation reference documents links www fda gov cdrh30
IDE RegulationReference Documents & Links (www.fda.gov/cdrh)
  • FDA Guidance for Financial Disclosure by Clinical Investigators
  • FDA Guidance for IRBs & Clinical Investigators
  • FDA Guidance for Monitoring Clinical Investigations
  • FDA/ORA Compliance Program Guidance for Bioresearch Monitoring of Clinical Investigations
  • FDA CDRH Device Advice